Quantcast
Last updated on April 16, 2014 at 6:45 EDT

Latest Tenofovir Stories

2010-06-17 06:00:00

HAIKOU, China, June 17 /PRNewswire-Asia/ -- Kun Run Biotechnology, Inc. (the "Company" or "Kun Run") (OTC Bulletin Board: KURU), a leading bio-pharmaceutical company in China focusing on manufacturing and sales of peptide-based and small molecule drugs, today announced that they have obtained the manufacturing approval for Entecavir from the China State Food and Drug Administration (SFDA). Entecavir is an oral antiviral drug used in the treatment of Hepatitis-B infection. It works by...

2010-06-02 07:00:00

WALTHAM, Mass., June 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of HIV, Gilead and Tibotec (a wholly owned subsidiary of Johnson & Johnson) remain on track to launch three novel treatment options in the next two years - Gilead's Quad (a four drug, one pill, once-daily, regimen), Tibotec's rilpivirine and Gilead/Tibotec's rilpivirine/emtricitabine/tenofovir...

2010-05-24 13:19:33

New research presented at International Microbicides Conference Their scientific methods may have been quite different, but their conclusions were not. In asking whether drug resistance could be a problem if antiretroviral (ARV) drugs become a mainstay for HIV prevention, the two studies "“ one involving a mathematical model and the other assays of cells and tissue "“ arrived at the same answer. Resistance could happen if people who are unknowingly already infected use the...

2010-05-13 07:30:00

RESEARCH TRIANGLE PARK, N.C., May 13 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable...

2010-01-04 08:28:00

WALTHAM, Mass., Jan. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2018, the fixed dose coformulation of Tibotec's* rilpivirine and Gilead's Truvada will achieve blockbuster sales of more than $2 billion in the HIV drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor finding from the topic entitled Human Immunodeficiency Virus...

2009-10-06 09:26:00

NEW YORK, Oct. 6 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile http://www.reportlinker.com/p0151769/Reportlinker-Adds-Gilead-Sciences-Inc-PharmaVitae-Profile.html Introduction This analysis examines the historical and forecast performance for Gilead in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and...

2009-09-16 06:30:00

PITTSBURGH, Sept. 16 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 600 mg/300 mg/300 mg. Mylan's product represents the first-ever fixed-dose combination...

2009-09-13 12:00:00

PRINCETON, N.J. and SAN DIEGO, Sept. 13 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced results from an in vitro study evaluating TBR-652 in combination with lopinavir (LPV), darunavir (DRV), atazanavir (ATV), tenofovir (TDF), etravirine (ETV), and raltegravir (RAL) using the infectious replicative assay deCIPhR....

2009-08-18 10:15:00

PITTSBURGH, Aug. 18 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that Matrix Laboratories, an Indian company in which Mylan owns a controlling stake, has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for a fixed-dose combination (FDC) of Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Tablets, 600 mg/200 mg/300 mg. This...

f96e4396eb5e7fca3bc78a046c4de75f
2009-08-07 08:05:00

An arrangement between former President Bill Clinton's foundation and two drug corporations will decrease prices on medicines for patients with drug-defiant HIV in developing countries.One contract, with Mylan Inc., drops the yearly cost of four antiretroviral drugs that are a second kind of treatment when patients build up a resistance to the drugs that are initially used.The other arrangement, with Pfizer Inc., decreases the cost of several drugs.These contracts could help drugs "reach...